NAGE Stock Analysis: Buy, Sell, or Hold?
NAGE - Niagen Bioscience, Inc. Common Stock
$4.28
0.08 (1.90%)
▲
5d:
-9.13%
30d:
-15.25%
90d:
-35.54%
HOLD
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 06, 2026
Smart Money Accumulation
NAGE is down 9.9% this week, but smart money is accumulating calls. Top strike: $5 2026-05-15 with 898 OI. Call ratio: 100% View Scanner →
Strength: 9.9/10
Get Alerted When NAGE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NAGE shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: NAGE shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$15.52
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$9.64
55.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 23.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NAGE is currently trading at $4.28, which is considered oversold relative to its 30-day fair value range of $4.56 to $5.11. From a valuation perspective, the stock is trading at a discount (Forward PE: 12.4) compared to its historical average (23.1). Remarkably, the market is currently pricing in an annual earnings decline of 18.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, NAGE is in a strong downtrend. The price is currently testing key support at $4.16. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.60 (+217.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NAGE is in a strong downtrend. The price is currently testing key support at $4.16. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.60 (+217.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$4.56 -
$5.11
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.5%
Protect Your Profits
Holding NAGE? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 217.8% below Wall St target ($13.60)
- CAUTION: Recommendation downgraded due to -9.1% 5-day decline
Fair Price Analysis
30-Day Fair Range
$4.56 -
$5.11
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$0.54
(12.6%)
Support & Resistance Levels
Support Level
$4.16
Resistance Level
$4.95
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.41
Wall Street Target
$13.60
(+217.8%)
Revenue Growth (YoY)
16.2%
Earnings Growth (YoY)
-41.6%
Profit Margin
13.4%
Valuation Discount vs History
-18.7% cheaper
PE vs Historical
12.4 vs 23.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-18.7%
(market-implied from PE analysis)
1-Year Target
$3.85
(-10%)
2-Year Target
$3.47
(-19%)
3-Year Target
$3.12
(-27%)
3-Yr Target (if PE normalizes)
(PE: 12→23)
$5.81
(+36%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 30.2%)
$17.01
(+298%)
Base:
(SPY PE: 12.4, Growth: 30.2%)
$9.44
(+121%)
Bear:
(PE: 10.5, Growth: 30.2%)
$8.03
(+88%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (23x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 23.30 | Current EPS (TTM): $0.20
Bull Case
$8.84
(+88%)
Analyst growth 72.5%, PE expands to 25.6
Base Case
$8.04
(+71%)
Market implied 72.5%, PE stable at 23.3
Bear Case
$3.17
(-33%)
Severe decline -20.0%, PE contracts to 19.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.4 to 23.1
Stabilization Target:
$7.97
(+86.2%)
PE Expansion Potential:
+86.2%
Share & Embed Analysis
Last updated: March 31, 2026 6:21 AM ET
Data refreshes hourly during market hours. Next update: 7:21 AM
Data refreshes hourly during market hours. Next update: 7:21 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NAGE showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Ozan Pamir
BUY
4465 shares
2025-11-14
Ozan Pamir
BUY
2220 shares
2025-11-14
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 48 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 48 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 49 HOLD |
Advanced NAGE Option Strategies
Professional options setups generated by AI based on today's NAGE price and gamma walls.
